Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60-70 years.
CONCLUSIONS: Two-dose HBsAg/CpG 1018 provides a higher level of seroprotection against HBV than does a 3-dose vaccine (HBsAg/alum) with a similar safety profile in patients aged 60-70 years with type 2 diabetes mellitus. Study identifier: NCT02117934.
PMID: 31431412 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Hyer RN, Janssen RS Tags: Vaccine Source Type: research
More News: Allergy & Immunology | Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Hepatitis | Hepatitis B | Hepatitis Vaccine | International Medicine & Public Health | Smokers | Study | Vaccines